• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Ryaltris nasal spray approved in the EU

Glenmark Pharmaceuticals said that it plans to launch Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of allergic rhinitis in 16 European Union countries and the UK after finalizing marketing approval. Menarini Group will commercialize Ryaltris in some of the companies, including France, Italy, Spain, and the Balkans, under a December 2020 licensing agreement; Glenmark will market Ryaltris in the remaining countries.

Glenmark Executive VP, Business Head EMEA-L, Achin Gupta, commented, “Despite many treatments being available for allergic rhinitis, Glenmark is excited to launch Ryaltris as the only first line combination inhaler treatment option for patients across Europe. Upwards of 25% of the population in Europe suffers from the debilitating symptoms of allergic rhinitis, so we hope that Ryaltris will bring some of these real benefits – a simple inhaler, offering fast and effective relief.”

According to Glenmark, marketing applications for Ryaltris are under review in several countries, including Canada, Brazil, Malaysia, and Saudi Arabia, and Grandpharma intends to submit an IND in China within this financial year. The Russian Ministry of Health approved the nasal spray earlier this year. Glenmark also reports that Seqirus recently launched Ryaltris in South Africa, Ukraine and Uzbekistan and that Ryaltris is selling well in Australia after a 2020 launch by Seqirus. Rylatris was approved by the TGA in December 2019.

In the US, Hikma Pharmaceuticals acquired distribution rights to Ryaltris in February 2020.  The FDA issued a complete response letter to Glenmark’s NDA for Ryaltris in June 2019. Glenmark recently announced that Bausch Health has obtained Canadian rights to the nasal spray.

Read the Glenmark Pharmaceuticals press release.

Share

published on April 26, 2021

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews